摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-benzomalvin B | 157047-97-7

中文名称
——
中文别名
——
英文名称
(E)-benzomalvin B
英文别名
Benzomalvin B;(7E)-7-benzylidene-6-methylquinazolino[3,2-a][1,4]benzodiazepine-5,13-dione
(E)-benzomalvin B化学式
CAS
157047-97-7
化学式
C24H17N3O2
mdl
——
分子量
379.418
InChiKey
HXDZMNFJQNZXKW-RCCKNPSSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    612.1±65.0 °C(Predicted)
  • 密度:
    1.28±0.1 g/cm3(Predicted)
  • 溶解度:
    溶于二甲基亚砜

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    29
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.04
  • 拓扑面积:
    53
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (E)-benzomalvin B二甲基亚砜 为溶剂, 反应 0.5h, 生成 (Z)-benzomalvin B
    参考文献:
    名称:
    1H NMR Reassignment for Z/E-Benzomalvins B and Absolute Configuration of Benzomalvin C
    摘要:
    从中国南海软珊瑚中分离的海洋真菌曲霉中同时获得了苯并马来呋喃霉素 B、C 和 E(1、2 和 3)。根据核磁共振光谱数据并与之前文献报道的结构进行综合比较,阐明了它们的结构。研究了不同光照条件下 E-苯并吗啡乙(1)双键的稳定性,并在紫外 365 nm 照射下将 1 转化为 Z-苯并吗啡乙(1′)。其中,首次对文献中错误的 1′ 的 1H NMR 数据进行了重新分配。此外,还通过 X 射线单晶衍射首次报告了苯并吗啡 C(2)的绝对构型。
    DOI:
    10.1007/s10600-021-03347-5
  • 作为产物:
    描述:
    (-)-benzomalvin A 在 N-溴代丁二酰亚胺(NBS)偶氮二异丁腈1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下, 以 四氯化碳甲苯 为溶剂, 反应 6.0h, 生成 (E)-benzomalvin B
    参考文献:
    名称:
    通过分子内的氮杂-维蒂希反应进行的第一个全合成(-)-benzomalvin A和benzomalvin B
    摘要:
    描述了具有4(3 H)-喹唑啉酮和1,4-苯并二氮杂-5-基团的一个部分的(-)-苯并丙氨酸A的第一个全合成。通过分子内的氮杂-维蒂希反应作为关键反应,可以有效地构建6元和7元环骨架。基于使用特殊改性的纤维素作为固定相的HPLC分析,合成(-)-苯并丙氨酸A的对映体过量超过99.7%。此外,通过NMR研究和X射线晶体学分析对(-)-苯并马文敏A的特定构象动力学行为进行了研究,并且仅通过两步就容易地由(-)-苯并马文敏A合成苯并马文敏B。
    DOI:
    10.1016/s0040-4020(98)00437-2
点击查看最新优质反应信息

文献信息

  • Total Synthesis of Racemic Benzomalvin E, a Quinazolinone Isolated from <i>Pencilium sp</i>. FN070315 and Exploration to the Direct Synthesis of (<i>E</i>)-Benzomalvin B
    作者:Soumya Jyoti Basak、Jyotirmayee Dash
    DOI:10.1021/acs.joc.3c02687
    日期:2024.3.1
    We present the first total synthesis of (±) benzomalvin E, featuring a quinazolino moiety with a 6–6–6–7-fused tetracyclic skeleton containing three nitrogen atoms. The key transformation involves Cu-catalyzed intramolecular C–N arylation of quinazolinone, leading to a sclerotigenin analogue that undergoes nucleophilic addition with benzaldehyde, enabling the synthesis of (±) benzomalvin E in six linear
    我们首次全合成了 (±) 苯并马尔文 E,其特征是喹唑啉基部分具有包含三个氮原子的 6-6-6-7-稠合四环骨架。关键的转化涉及铜催化的喹唑啉酮分子内 C-N 芳基化,产生硬化素类似物,与苯甲醛进行亲核加成,从而能够通过六个线性步骤合成 (±) 苯并马尔文 E,总产率为 33%。通过二维NMR和单晶XRD分析验证了(±)苯并马尔文E的结构,并进一步转化为( E )-苯并马尔文B。
  • Benzomalvins, new suhstance P inhibitors from a Penicillium sp.
    作者:HAO H. SUN、COLIN J. BARROW、DAVID M. SEDLOCK、AMANDA M. GILLUM、RAYMOND COOPER
    DOI:10.7164/antibiotics.47.515
    日期:——
    In the course of screening microbial broths for neurokinin receptor antagonists, a series of new benzodiazepines, benzomalvins A (1), B (2) and C (3), has been isolated from the culture broth of a fungus identified as a Penicillium sp. Benzomalvin A (1) showed inhibitory activity against substance P with Ki values of 12, 42 and 43 fXM at the guinea pig, rat and human neurokinin NK1 receptors, respectively. Benzomalvins B (2) and C (3) were only weakly active. The structures of these compounds were determined by spectroscopic methods including MS measurements and NMR analysis.
  • The first total synthesis of (−)-benzomalvin A and benzomalvin B via the intramolecular aza-Wittig reactions
    作者:Toshiyuki Sugimori、Tomohiro Okawa、Shoji Eguchi、Akikazu Kakehi、Eiji Yashima、Yoshio Okamoto
    DOI:10.1016/s0040-4020(98)00437-2
    日期:1998.7
    The first total synthesis of ()-benzomalvin A, which possesses 4(3H)-quinazolinone and 1,4-benzodiazepin-5-one moieties, was described. Both of 6- and 7-membered ring skeletons were efficiently constructed by the intramolecular aza-Wittig reactions as the key reactions. The enantiomeric excess of synthetic ()-benzomalvin A was more than 99.7% based on HPLC analysis using specially modified cellulose
    描述了具有4(3 H)-喹唑啉酮和1,4-苯并二氮杂-5-基团的一个部分的(-)-苯并丙氨酸A的第一个全合成。通过分子内的氮杂-维蒂希反应作为关键反应,可以有效地构建6元和7元环骨架。基于使用特殊改性的纤维素作为固定相的HPLC分析,合成(-)-苯并丙氨酸A的对映体过量超过99.7%。此外,通过NMR研究和X射线晶体学分析对(-)-苯并马文敏A的特定构象动力学行为进行了研究,并且仅通过两步就容易地由(-)-苯并马文敏A合成苯并马文敏B。
  • 1H NMR Reassignment for Z/E-Benzomalvins B and Absolute Configuration of Benzomalvin C
    作者:Rong Chao、Yan-Wei Wu、Ling Lu、Wei-Feng Xu、Chang-Yun Wang、Chang-Lun Shao
    DOI:10.1007/s10600-021-03347-5
    日期:2021.3
    Benzomalvins B, C, and E (1, 2, and 3) were simultaneously obtained from the marine fungus Aspergillus sp. isolated from the soft coral Sinularia sp., collected from South China Sea. Their structures were elucidated on the basis of NMR spectroscopic data and by comprehensive comparison with those previously reported in the literature. The stability of the double bond of E-benzomalvin B (1) under different light conditions was investigated, and 1 was transformed to Z-benzomalvin B (1′) with UV 365 nm irradiation. In particular, the incorrect 1H NMR data of 1′ in the literature was reassigned for the first time. Moreover, the absolute configuration of benzomalvin C (2) was also reported for the first time by X-ray single crystal diffraction.
    从中国南海软珊瑚中分离的海洋真菌曲霉中同时获得了苯并马来呋喃霉素 B、C 和 E(1、2 和 3)。根据核磁共振光谱数据并与之前文献报道的结构进行综合比较,阐明了它们的结构。研究了不同光照条件下 E-苯并吗啡乙(1)双键的稳定性,并在紫外 365 nm 照射下将 1 转化为 Z-苯并吗啡乙(1′)。其中,首次对文献中错误的 1′ 的 1H NMR 数据进行了重新分配。此外,还通过 X 射线单晶衍射首次报告了苯并吗啡 C(2)的绝对构型。
查看更多

同类化合物

阿斯普尼辛B 阿斯普尼辛 D 阿斯普尼辛 苯佐莫文 新骏河毒素 乙酰胺,N-(4-硝基-2-吡啶基)-,氧化(9CI) TAK960抑制剂 PLK1抑制剂(RO3280) 8H-嘧啶并[4,5-b][1,4]二氮杂卓 8-甲基-5,9-二氢-6H-嘧啶并[4,5-b][1,4]重氮基庚英-6-酮 6H-嘧啶并[4,5-b][1,4]二氮杂卓 4-甲基-6,11-二氢-3H-嘧啶并[4,5-b][1,5]苯并二氮杂卓-2,5-二酮 2-氯-7,7-二氟-5-甲基-5,7,8,9-四氢-6H-嘧啶基[4,5-B][1,4]二氮杂-6-酮 2-氯-5-甲基-5,7,8,9-四氢-6H-嘧啶[4,5-B][1,4]二氮杂6-酮 1H-嘧啶并[4,5-b][1,4]二氮杂卓 4-amino-8-(1,3-benzodioxol-5-yl)-6-phenyl-8,9-dihydro-7H-pyrimido[4,5-b][1,4]diazepine 2-(2-Bromo-4-isopropyl-phenyl)-4-methyl-6-pentyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 2-chloro-8-(trifluoromethyl)-6H,11H-benzo[b]pyrimidino[5,4-f]-1,4-diazaperhydroepin-5-one 4,5,6,7-tetrahydro-2,4-diphenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione 4,5,6,7-tetrahydro-4-methyl-2-phenyl-4,7a,12b-triazadibenzo[e,g]azulene-1,3,8-trione N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-5-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-2-methyl-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6-oxo-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-fluorophenyl)-N-(4-((8-methoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-11H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide N-(4-((8,9-dimethoxy-6,11-dihydro-5H-benzo[e]pyrimido[5,4-b][1,4]diazepin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide di-tert-butyl (1r,4r)-4-(4-(9-cyclohexyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxybenzamido)cyclohexyl phosphate 2-(2-Bromo-4-isopropyl-phenyl)-6-(1-ethyl-propyl)-4-methyl-6,7,8,9-tetrahydro-2H-2,3,5,6,9a-pentaaza-benzo[cd]azulen-1-one 7,8,9,10-tetrahydro-10-hydroxy-9-heptyl-[1,4]diazepino[1,2,3-g,h]purine 7,8,9,10-tetrahydro-10-hydroxy-9-methyl-9-propyl[1,4]diazepino[1,2,3-g,h]purine 6-cyclopentyl-9-[(3-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one 6-cyclopentyl-9-[(2-methoxyphenyl)amino]-2-methyl-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-3-one tert-butyl 8,10-dibromo-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate tert-butyl 8,10-dimethyl-7-oxo-1,2,5,5a,6,7-hexahydro-[1,4]diazepino[1,7-a]quinazoline-3(4H)-carboxylate 11-Diallylaminoacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 6-butyl-11-diallylaminoacetyl-2-phenyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 11-chloroacetyl-6-isopropyl-5,6-dihydropyrimido[4,5-b][1,5]benzodiazepin-5-one 4-[(2-cyclopentyl-4,4,6-trimethyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]benzoic acid 4-[(2-cyclopentyl-6-methyl-5-oxo-2,6,9,11-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-10-yl)amino]-3-methoxy-N-(4-piperidyl)benzamide 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-N-(1-ethyl-4-piperidyl)-3-methoxy-benzamide 8-(4-chlorophenyl)-6-phenyl-9H-pyrimido[4,5-b][1,4]diazepin-4-ol 1-chloro-7-methoxy-8-(3-morpholin-4-yl-propoxy)-10,11-dihydro-5H-2,4,5,11-tetraaza-dibenzo[a,d]cycloheptene 4-[(6-cyclopentyl-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl)amino]-3-methoxy-N-methyl-benzamide (S)-tert-butyl (4-chloro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-7-yl)carbamate 3-methoxy-4-[[6-(2-methoxyethyl)-2-methyl-3-oxo-2,6,8,10-tetrazabicyclo[5.4.0]undeca-7,9,11-trien-9-yl]amino]-N-(1-methyl-4-piperidyl)benzamide (9aS,9R)-4-chloro-N-(4-methylphenyl)-9a,10,11,12-tetrahydro-9H-pyrimido[4,5-b]dipyrrolo[1,2-d:2',1'-g][1,4]diazepin-9-amine